Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report

Abstract

Venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia and acute myeloid leukemia, has been rarely associated with autoimmune hemolytic anemia, mostly in chronic lymphocytic leukemia. We report the first case of venetoclax-triggered autoimmune hemolytic anemia in acute myeloid leukemia secondary to chronic myelomonocytic leukemia. An 80-year-old man developed abrupt warm autoimmune hemolytic anemia 4 days after venetoclax initiation with azacitidine. Hemolysis resolved rapidly after venetoclax withdrawal and corticosteroid therapy. Rechallenge led to compensated hemolysis. This case supports venetoclax causality and highlights that autoimmune hemolytic anemia can occur beyond lymphoid malignancies. Clinicians should monitor for autoimmune cytopenias during venetoclax therapy, even in myeloid disorders.

Keywords

Bcl2 inhibitor chronic myelomonocytic leukemia side effect autoimmunity hematology pharmacovigilance safety AIHA AML CMML

Introduction

Venetoclax is an oral BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in combination with hypomethylating agents. Its main toxicities include cytopenias, gastrointestinal events, and tumor lysis syndrome. Reports of venetoclax-triggered autoimmune hemolytic anemia (AIHA) have been almost exclusively described in CLL, a context in which underlying immune dysregulation is known to predispose patients to autoimmunity. This has led to the perception that AIHA in this setting may be primarily disease-related rather than drug-related. Pharmacovigilance data suggest that venetoclax-triggered AIHA could also occur in other hemopathies (prolymphocytic T-cell leukemia), but there are no published reports outside lymphoid malignancies.¹

Here, we report a case of venetoclax-triggered AIHA in a patient with AML secondary to chronic myelomonocytic leukemia (CMML), suggesting that this adverse event may represent a drug-class effect.

Timeline

April 15, 2023: Diagnosis of CMML. Favorable response to erythropoietin (EPO), routine outpatient follow-up.

June 12, 2024: AML transformation.

June 24, 2024: Start of treatment with azacitidine and venetoclax.

June 27, 2024: Onset of hemolytic anemia, venetoclax was withdrawn while azacitidine was continued.

June 28, 2024: Beginning of treatment with corticosteroids.

July 5, 2024: Decrease in corticosteroids.

July 11, 2024: End of corticosteroid treatment; second cycle of azacitidine and restart of venetoclax, with recurrence of chronic compensated hemolysis since. Continuation of treatments every month, and persistence of compensated hemolysis.

Narrative

An 80-year-old man with a history of CMML presented with AML transformation. He had received EPO with transient benefit. At AML progression, white blood cell count was 61 with 19 g/L monocytes. Bone marrow examination showed 16% blasts with monocytoid features, along with 10% monocytes and persistent dysmyelopoiesis. Karyotype was normal, with no 17p deletion.

Treatment with azacitidine and venetoclax (100 mg/day for 7 days) was initiated after rasburicase prophylaxis. No cases of AIHA have been reported in association with rasburicase or azacitidine, and no other treatment has been started recently.

Baseline hemoglobin was 11.4 g/dL. On day 4, the patient developed a sudden, dramatic drop in hemoglobin to 7.1 g/dL, with reticulocytosis (384 g/L), elevated LDH (lactate dehydrogenase: 3384 U/L), unconjugated hyperbilirubinemia (31 µmol/L), undetectable haptoglobin, and a positive direct antiglobulin test (IgG) (Table 1). White blood cell counts had decreased (leukocytes 28 g/L, monocytes 3 g/L), platelet counts were normal, and tumor lysis syndrome was controlled. These findings confirmed warm AIHA.

Table 1.

Summary of diagnostic tests and results.

Test name	Result	Normal range	Interpretation
Monocyte immunophenotyping	Classical monocytes MO1 98%	<94%	Diagnosis of CMML
Bone marrow aspiration	Blasts 16% + monoblasts 10%	<5%	AML transformation
Direct antiglobulin test	Positive IgG+++	Negative	AIHA
LDH	3384 UI/L	<250 UI/L	Elevated
Bilirubin	31 µmol/L	<21 µmol/L	Elevated
Haptoglobin	<0.1 g/L	0.3–2 g/L	Undetectable

AIHA: autoimmune hemolytic anemia; AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; LDH: lactate dehydrogenase.

Venetoclax was withdrawn while azacitidine was continued, as venetoclax was considered the most likely causative agent after discussion with our clinical pharmacists. Rasburicase had been administered as a single dose and was already stopped. We had planned to stop azacitidine if there had not been a rapid improvement in hemolysis, which fortunately was not necessary. Corticosteroids (prednisone 1 mg/kg) were initiated, leading to rapid hematological recovery, allowing steroid taper after 7 days and cessation after 14 days.

The decision to re-administer venetoclax was carefully discussed in a multidisciplinary team meeting, weighing the benefit–risk balance. We also consulted our clinical pharmacists and reviewed pharmacovigilance data. Considering the rapid and favorable evolution of AIHA, the expected significant benefit of venetoclax, the absence of equally effective alternatives for this patient, and his request to continue treatment, we decided to resume venetoclax under close in-hospital daily monitoring of hemolysis parameters (complete blood count, reticulocytes, LDH, bilirubin, haptoglobin) to ensure patient safety. Corticosteroids and rituximab were considered; however, given the patient’s age and vulnerability to infections, and the absence of previously reported cases of AIHA under venetoclax in myeloid malignancies, our suspicion of a venetoclax-related AIHA was initially uncertain and these treatments were therefore not initiated.

During the next cycle, venetoclax was thus cautiously reintroduced in combination with azacitidine. We observed recurrence of hemolysis, but it remained moderate and compensated, without clinically significant consequences.

Treatment is pursued every month, with persistence of chronic compensated hemolysis ever since. The patient is being closely monitored for potential long-term risks of this compensated hemolysis, including thrombosis and renal impairment. Despite these risks, he is tolerating the treatment very well, does not require transfusions, and the benefit–risk balance remains favorable for this now 83-year-old patient.

Diagnostics

Patient perspective

The patient has confidence in the treatment and its management and tolerates venetoclax well.

He is proud that his experience is being shared. He continues to be followed regularly in the clinic and remains active in his personal life.

Discussion

This is one of the first reported cases of venetoclax-triggered AIHA outside of CLL, and the first in a myeloid malignancy. We acknowledge that the patient’s underlying CMML, a condition associated with a higher baseline risk of autoimmunity, represents an important confounding factor. Nevertheless, the chronology of events, absence of alternative triggers, and rapid resolution following drug withdrawal support a contributory role of venetoclax in the development of AIHA in this patient. The causative role of venetoclax was considered “probable/likely” according to the WHO–UMC criteria, and a “definite adverse drug reaction” (9/12) according to the Naranjo Adverse Drug Reaction Probability Scale, consistent with a scenario in which the drug precipitated an autoimmune reaction in a predisposed individual.

AIHA associated with hematologic malignancies

Autoimmune cytopenias are a common complication of CLL, which may predispose patients to such events; indeed, AIHA can occur in 10%–15% of CLL patients. The association between AIHA and myeloid pathologies (particularly CMML or AML) is less commonly recognized, even though some single-center studies report incidences of up to 20% in the case of CMML.² AIHA may be underreported in AML, as it can be attributed to disease progression, concurrent infections, or overlapping cytopenias due to myelosuppression.

Literature of venetoclax-triggered AIHA in CLL context

Several cases of venetoclax-triggered AIHA have been reported, almost exclusively in CLL patients^3–5 (see Tables 2 and 3).

Table 2.

Case reports of venetoclax-triggered AIHA in CLL patients.

Patient	Context	Management	Outcome	Rechallenge	Reference
62-Year-old woman	AIHA after 17 cycles of venetoclax for CLL	Venetoclax discontinuation, dexamethasone, and four weekly rituximab infusions	Favorable hematologic response	Venetoclax was not resumed	Abdel-Samad and Sughayar³
73-Year-old man	AIHA during dose escalation of venetoclax in second-line for CLL (first line: cyclophosphamide and fludarabine)	Venetoclax discontinuation and corticosteroids	Complete response	Venetoclax was resumed with recurrent AIHA episode requiring venetoclax discontinuation and steroid reintroduction, with a favorable response	Hadjiaggelidou et al.⁶

AIHA: autoimmune hemolytic anemia; CLL: chronic lymphocytic leukemia.

Table 3.

Case series of venetoclax-triggered AIHA in CLL patients.

Case series	Reported auto-immune cytopenias	References
350 CLL patients treated with venetoclax	AIHA was reported in 10 patients (3%)	Davids et al.⁷
100 CLL patients treated with venetoclax	Autoimmune cytopenias occurred in 7% of cases (vs 1% on ibrutinib and 0.9% on idelalisib)	Vitale et al.⁸
107 CLL patients treated with venetoclax	AIHA was reported in 7% of patients	Stilgenbauer et al.⁹
258 CLL patients treated with venetoclax	AIHA was reported in four patients (1.5%), including one fatal	Kater et al.¹⁰
123 patients (40 AML, 69 CLL, and 15 others)	AIHA occurred in 2% of cases (three patients: two with CLL including one fatal, and one with prolymphocytic T-cell leukemia at a dose of 1000 mg/day). No case of AIHA was reported in AML patients	Talbot et al.¹

AIHA: autoimmune hemolytic anemia; AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia.

These data suggest that venetoclax may predispose to AIHA in CLL, although this complication is not consistently observed across studies,^11,12 and its incidence in myeloid hemopathies is not known.

Potential mechanisms of venetoclax-triggered AIHA

The mechanism by which venetoclax may contribute to AIHA remains incompletely understood. Emerging evidence suggests a central role of BCL-2, as it is essential for lymphocyte development and maintenance of peripheral tolerance.¹³ Several studies have shown that BCL-2 inhibition can lead to an increase in regulatory T cells (Tregs),¹⁴ but with reduced suppressive capacity,¹⁵ potentially favoring autoimmunity. In addition, BCL-2 inhibition has been reported to enhance dendritic cell activation and anti-tumor immune responses,¹⁶ potentially promoting an autoreactive immune environment.

The rapid onset of AIHA in our patient (4 days) suggests that underlying immune dysregulation from CMML, combined with transient disruption of tolerance by venetoclax, precipitated the autoimmune response.

The absence of reported AIHA cases with azacitidine monotherapy supports a contributory role of venetoclax. However, AIHA in this setting is likely venetoclax-triggered rather than purely venetoclax-induced, as venetoclax may unmask or exacerbate a pre-existing autoimmune predisposition (as seen in CLL but also in CMML²).

While this may represent a class effect, data on immune-mediated adverse events with other BCL-2 family inhibitors remain limited, and further mechanistic studies are needed to clarify these observations.

Conclusion

Clinicians should be aware of this rare but potentially severe complication. Close monitoring for autoimmune hemolysis should be included in the safety surveillance of patients treated with venetoclax, especially as its indications expand. We could also suggest baseline autoimmune screening before starting venetoclax (e.g. direct Coombs test, autoimmune serology), particularly in patients with underlying autoimmune risk, such as patients with CLL, but also CMML. Early recognition of AIHA and prompt withdrawal of venetoclax, together with corticosteroids, allows rapid resolution. Rechallenge may be cautiously considered on a case-by-case basis.

Footnotes

Acknowledgements

We would like to thank the patient for his consent and the entire team for their care.

ORCID iD

Guillemette Fouquet

Ethical considerations

The study was conducted in accordance with Helsinki’s declaration. This case report adheres to the CARE guidelines.

Consent to participate

Informed oral and written consent was obtained from the patient prior to submission.

Author contributions

Conception and design: K.B., G.F. Collection and assembly of data: K.B., P.L., S.M., G.F. Manuscript – writing and editing: K.B., P.L., B.G., S.M., G.F.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Talbot

Debureaux

P-E

Lillo-Le Louet

, et al. Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years. Ther Adv Hematol 2025; 16: 20406207251343116.

Zahid

Barraco

Lasho

, et al. Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 2017; 58(6): 1488–1493.

Abdel-Samad

Sughayar

Can treatment with venetoclax for chronic lymphocytic leukemia (CLL) result in autoimmune hemolytic anemia?. Am J Case Rep 2021; 22: e928514.

Carriles

Ordóñez-Fernández

Arias-Martínez

, et al. Autoimmune hemolytic anemia, adverse event to venetoclax. Farm Hosp 2019; 43(5): 166–167.

Yan

Guo

Wang

, et al. Clinical pharmacology and side effects of venetoclax in hematologic malignancies. Curr Drug Metab 2025; 25(8): 564–575.

Hadjiaggelidou

Douganiotis

Tsirou

, et al. A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2021; 62(12): 3054–3056.

Davids

Hallek

Wierda

, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res 2018; 24(18): 4371–4379.

Vitale

Salvetti

Griggio

, et al. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood 2021; 137(25): 3507–3517.

Stilgenbauer

Eichhorst

Schetelig

, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17(6): 768–778.

10.

Kater

Arslan

Demirkan

, et al. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. Lancet Oncol 2024; 25(4): 463–473.

11.

Roberts

Davids

Pagel

, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374(4): 311–322.

12.

CADTH Pan-Canadian Oncology Drug Review. Initial clinical guidance report: venetoclax (Venclexta) rituximab for chronic lymphocytic leukemia (pERC meeting: March 21, 2019). CADTH, 2019.

13.

Tischner

Woess

Ottina

, et al. Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis 2010; 1(6): e48.

14.

Gabriel

Bon

Chen

, et al. Distinctive expression of Bcl-2 factors in regulatory T cells determines a pharmacological target to induce immunological tolerance. Front Immunol 2016; 7: 73.

15.

Tischner

Gaggl

Peschel

, et al. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J Autoimmun 2012; 38(1): 59–69.

16.

Zhao

Liu

Mao

, et al. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov 2023; 13(11): 2448–2469.